
Correction: Supplementary drug treatment to reduce weight in adolescents with severe obesity

CORRECTION

JOHANNES ROLIN

RØNNAUG ASTRI ØDEGÅRD

VIKTORIA VEDELER AMUNDSEN

UNNI METTE STAMNES KÖPP

ANE KOKKVOLL

PÉTUR BENEDIKT JÚLÍUSSON

JØRAN HJELMESÆTH

Tidsskr Nor Legeforen 2022; 142: 1250–1.

On page 1250 of issue no. 14/2022 of the Journal of the Norwegian Medical Association, the following should be written in the English version of the article: Orlistat (Xenical) is *not* approved for the treatment of obesity in children aged 12 years or older, *and* is associated with a small weight-reducing effect on average (< 3 %) and unpleasant side effects (5).

We apologise for the error, which has been corrected online.

Publisert: 12 January 2023. Tidsskr Nor Legeforen. DOI: 10.4045/tidsskr.23.0028
Copyright: © Tidsskriftet 2026 Downloaded from tidsskriftet.no 24 June 2026.